A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
Public ClinicalTrials.gov record NCT05871541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
Study identification
- NCT ID
- NCT05871541
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2023
- Primary completion
- Mar 24, 2024
- Completion
- Mar 24, 2024
- Last update posted
- Sep 18, 2024
2023 – 2024
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CenExel RCA | Hollywood | Florida | 33024 | — |
| CenExel FCR | Tampa | Florida | 33613 | — |
| CenExel HRI | Berlin | New Jersey | 08009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Herpes Zoster (HZ) trials
Other public records listing Herpes Zoster (HZ). Sorted by last update posted; newest first. Not a recommendation.
- NCT06581575: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Active, not recruiting
- NCT04128189: Shingrix in Renal Transplant Recipients Recruiting
- NCT06903078: A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster. Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05871541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05871541 live on ClinicalTrials.gov.